North America Coagulation Market Forecast to 2030

North America Coagulation Market Forecast to 2030 – Regional Analysis – by Disease Indications (Vitamin K Deficiency, Liver Disease, Disseminated Intravascular Coagulation & Pulmonary Embolism, Development of Circulating Anticoagulants, Hemophilia, Von Willebrand’s Disease, and Others), Type [Clinical Laboratory Analyzers (Controls & Calibrators, Assays & Reagents, Instruments/Systems, Coagulation Factors, and Others) and Point-of-Care Testing Analyzers], Offering [Diagnosis (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimmer Testing, Platelets Function Testing, and Others) and Treatment (Anti-Fibrinolytic Drugs, Birth Control Pills, Desmopressin & Immunosuppressive Medicines, Vitamin K Supplements, Blood Thinners, Thrombin Inhibitors or Thrombolytics, Replacement Therapy, Catheter-Assisted Thrombus Removal, and Others)], Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Others), and End User (Clinical Laboratories, Hospitals, and Others)

Send Enquiry

$2,840$4,440

Description

The North America coagulation market was valued at US$ 2,712.64 million in 2022 and is expected to reach US$ 4,633.26 million by 2030; it is estimated to grow at a CAGR of 6.9% from 2022 to 2030.

Increasing Prevalence of Blood Disorders Fuel North America Coagulation Market

Hemophilia A is one of the common X-linked recessive disorders and the second most common inherited clotting factor deficiency after von Willebrand disease, according to the National Organization of Rare Disorders. Also, ~1 in 5,000 male infants suffers from hemophilia A in the US. According to the Global Hemophilia Care 2020 study, 393,658 bleeding disorders cases have been recognized and documented worldwide over time, including 241,535 hemophilia cases, 87,729 von Willebrand disease cases, and 64,394 other bleeding disorder cases. According to the National Library of Medicine (NLM), ~30,000-33,000 men were affected by hemophilia in the US in 2020.

As per the reports from the American Cancer Society (CLL), the US recorded ~21,250 new cases of chronic lymphocytic leukemia in 2021. A February 2020 update from the Centers for Disease Control and Prevention (CDC) states that the number of people in the US affected by deep vein thrombosis could reach 900,000 (1 to 2 per 1,000). The same source estimates that in the US 60,000-100,000 Americans die yearly from venous thromboembolism.

According to the US Department of Health & Human Services, ~100,000 Americans were diagnosed with sickle cell disease (SCD) in 2020, which is one of the most commonly inherited blood disorders. In addition, the number of people suffering from SCD is expected to grow by ~30% by 2050. The National Organization for Rare Disorders stated that immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affected ~66 adults per 1 million in the US each year in 2022. Therefore, the rising prevalence of blood disorders drives the coagulation market growth.

North America Coagulation Market Overview

The North America coagulation market is segmented into the US, Canada, and Mexico. North America accounts for a significant market share owing to the growing incidences of blood disorders, increasing occurrence of cardiovascular diseases such as atrial fibrillation (AFib), and the presence of major market players engaged in new and existing product developments. The US holds the largest share of the coagulation market in North America. The burgeoning cases of blood disorders, growing prevalence of cardiovascular diseases, and government support for preventing blood disorders are anticipated to boost the North America coagulation market growth during 2022-2030.

North America Coagulation Market Revenue and Forecast to 2030 (US$ Million)

North America Coagulation Market Segmentation

The North America coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the North America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand’s disease, and others. The liver disease segment held the largest North America coagulation market share in 2022.

Based on type, the North America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger North America coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the North America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger North America coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the North America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest North America coagulation market share in 2022.

By end user, the North America coagulation market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held the largest North America coagulation market share in 2022.

Based on country, the North America coagulation market is categorized into the US, Canada, and Mexico. The US dominated the North America coagulation market in 2022.

Diagnostica Stago Inc, F Hoffmann-La Roche Ltd, Genrui Biotech Co, Ltd, Helena Laboratories Corporation, Horiba Ltd, ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti., Siemens Healthineers AG, Sysmex Corp, and Transasia Bio-Medicals Ltd are some of the leading companies operating in the North America coagulation market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 6.9% CAGR, the North America Coagulation Market is Speculated to be Worth US$ 4,633.26 Million by 2030, Says the Research Team

According to the Research Team’ research, the North America coagulation market was valued at US$ 2,712.64 million in 2022 and is expected to reach US$ 4,633.26 million by 2030, registering a CAGR of 6.9% from 2022 to 2030. Development of point-of-care (POC) coagulation analyzers and increasing prevalence of blood disorders are among the critical factors attributed to the North America coagulation market expansion.

A rapid, reliable assessment of hemostasis is essential for patients suffering from trauma or other bleeding problems. Due to the constraints of sample preparation and analytical process, routine coagulation assays cannot analyze clot formation, and their results can be obtained only after 30-90 minutes. POC devices such as platelet function test, viscoelastic coagulation tests, blood gas analysis, and other coagulometers are available for assessment of hemostasis. A POC measurement tool can be used inside and outside the hospital as a decision-making and management tool. When time is paramount, POC analyzers provide immediate, actionable results in emergency rooms, coronary care units, surgery, and procedure suites. In addition to outpatient clinics and physicians’ offices, these devices can assist in patient management in pharmacies, care centers, and patients’ homes. POC coagulation analyzers offer timely results without compromising diagnostic quality control provided by central labs. In POC testing, it is important to provide fast results, along with accuracy and quality assurance.

In 2021, Siemens Healthineers launched fully automated CN-3000 and CN-6000 systems, which are mid- and high-volume handheld POC coagulation testing devices. The FDA cleared Siemens Healthineers’ Xprecia Stride Coagulation Analyser in 2016, as a POC coagulation analyzer device. The device has demonstrated prothrombin time/international normalized ratio (PT/INR) testing performance equivalence to Roche CoaguChek XS.

Thus, the growing developments in POC coagulation analyzers are expected to boost the coagulation market growth during the forecast period.

On the contrary, high costs associated with coagulation analyzers hampers the growth North America coagulation market.

Based on disease indication, the North America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand’s disease, and others. The liver disease segment held 54.0% share of the North America coagulation market in 2022, amassing US$ 1,464.05 million. It is projected to garner US$ 2,493.22 million by 2030 to expand at 6.9% CAGR during 2022-2030.

Based on type, the North America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held 66.7% share of the North America coagulation market in 2022, amassing US$ 1,808.71 million. It is projected to garner US$ 2,937.27 million by 2030 to expand at 6.2% CAGR during 2022-2030. Clinical laboratory analysers is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the North America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 64.5% share of the North America coagulation market in 2022, amassing US$ 1,748.38 million. It is projected to garner US$ 2,971.43 million by 2030 to expand at 6.9% CAGR during 2022-2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the North America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 59.3% share of North America coagulation market in 2022, amassing US$ 1,608.88 million. It is projected to garner US$ 2,782.91 million by 2030 to expand at 7.1% CAGR during 2022-2030.

By end user, the North America coagulation market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held 60.2% share of North America coagulation market in 2022, amassing US$ 1,634.17 million. It is projected to garner US$ 2,831.83 million by 2030 to expand at 7.1% CAGR during 2022-2030.

Based on country, the North America coagulation market is categorized into the US, Canada, and Mexico. The US held 84.1% share of North America coagulation market in 2022, amassing US$ 2,279.97 million. It is projected to garner US$ 3,846.07 million by 2030 to expand at 6.8% CAGR during 2022-2030.

Key players operating in the North America coagulation market are Diagnostica Stago Inc, F Hoffmann-La Roche Ltd, Genrui Biotech Co, Ltd, Helena Laboratories Corporation, Horiba Ltd, ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti., Siemens Healthineers AG, Sysmex Corp, and Transasia Bio-Medicals Ltd, among others.

In Feb 2021, Siemens Healthineers and Sysmex Extend Hemostasis Agreement. Siemens Healthineers and Sysmex Corporation announced the renewal of the companies’ long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers will distribute the new Sysmex CN Systems.

In Aug 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America coagulation market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America coagulation market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the coagulation market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Coagulation Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Increasing Prevalence of Blood Disorders
4.1.2 Rising Prevalence of Cardiovascular Diseases
4.2 Market Restraints
4.2.1 High Costs Associated with Coagulation Analyzers
4.3 Market Opportunities
4.3.1 Growing Organic and Inorganic Strategies by Key Market Players
4.4 Future Trends
4.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
4.5 Impact Analysis
5. Coagulation Market – North America Market Analysis
5.1 North America Coagulation Market Revenue (US$ million), 2022 – 2030
6. North America Coagulation Market – Revenue and Forecast to 2030 – by Disease Indication
6.1 Overview
6.2 North America Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
6.3 Vitamin K Deficiency
6.3.1 Overview
6.3.2 Vitamin K Deficiency: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liver Disease
6.4.1 Overview
6.4.2 Liver Disease: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
6.5.1 Overview
6.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Development of Circulating Anticoagulant
6.6.1 Overview
6.6.2 Development of Circulating Anticoagulant: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Hemophilia
6.7.1 Overview
6.7.2 Hemophilia: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.8 Von Willebrand’s Disease
6.8.1 Overview
6.8.2 Von Willebrand’s Disease: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
6.9 Others
6.9.1 Overview
6.9.2 Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Coagulation Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 North America Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Clinical Laboratory Analyzers
7.3.1 Overview
7.3.2 Clinical Laboratory Analyzers: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 North America Coagulation Market, by Clinical Laboratory Analyzers
7.4 Point-of-Care Testing Analyzers
7.4.1 Overview
7.4.2 Point-of-Care Testing Analyzers: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Coagulation Market – Revenue and Forecast to 2030 – by Offering
8.1 Overview
8.2 North America Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
8.3 Diagnosis
8.3.1 Overview
8.3.2 Diagnosis: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 North America Coagulation Market, by Diagnosis
8.4 Treatment
8.4.1 Overview
8.4.2 Treatment: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.1 North America Coagulation Market, by Treatment
9. North America Coagulation Market – Revenue and Forecast to 2030 – by Technology
9.1 Overview
9.2 North America Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
9.3 Optical Technology
9.3.1 Overview
9.3.2 Optical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Mechanical Technology
9.4.1 Overview
9.4.2 Mechanical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Electrochemical Technology
9.5.1 Overview
9.5.2 Electrochemical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Coagulation Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 North America Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Clinical Laboratories
10.3.1 Overview
10.3.2 Clinical Laboratories: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Hospitals
10.4.1 Overview
10.4.2 Hospitals: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Coagulation Market – Country Analysis
11.1 North America Coagulation Market, Revenue and Forecast to 2030
11.1.1.1 North America Coagulation Market, by Country
11.1.1.2 US
11.1.1.2.1 Overview
11.1.1.2.2 US Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.2.3 US Coagulation Market, by Disease Indication
11.1.1.2.4 US Coagulation Market, by Type
11.1.1.2.4.1 US Coagulation Market, by Clinical Laboratory Analyzers
11.1.1.2.5 US Coagulation Market, by Offering
11.1.1.2.5.1 US Coagulation Market, by Diagnosis
11.1.1.2.5.2 US Coagulation Market, by Treatment
11.1.1.2.6 US Coagulation Market, by Technology
11.1.1.2.7 US Coagulation Market, by End User
11.1.1.3 Canada
11.1.1.3.1 Overview
11.1.1.3.2 Canada Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.3.3 Canada Coagulation Market, by Disease Indication
11.1.1.3.4 Canada Coagulation Market, by Type
11.1.1.3.4.1 Canada Coagulation Market, by Clinical Laboratory Analyzers
11.1.1.3.5 Canada Coagulation Market, by Offering
11.1.1.3.5.1 Canada Coagulation Market, by Diagnosis
11.1.1.3.5.2 Canada Coagulation Market, by Treatment
11.1.1.3.6 Canada Coagulation Market, by Technology
11.1.1.3.7 Canada Coagulation Market, by End User
11.1.1.4 Mexico
11.1.1.4.1 Overview
11.1.1.4.2 Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million)
11.1.1.4.3 Mexico Coagulation Market, by Disease Indication
11.1.1.4.4 Mexico Coagulation Market, by Type
11.1.1.4.4.1 Mexico Coagulation Market, by Clinical Laboratory Analyzers
11.1.1.4.5 Mexico Coagulation Market, by Offering
11.1.1.4.5.1 Mexico Coagulation Market, by Diagnosis
11.1.1.4.5.2 US Coagulation Market, by Treatment
11.1.1.4.6 Mexico Coagulation Market, by Technology
11.1.1.4.7 Mexico Coagulation Market, by End User
12. Coagulation Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Coagulation Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Siemens Healthineers AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Diagnostica Stago, Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sysmex Corp
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Helena Laboratories Corporation
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Genrui Biotech Co., Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Transasia Bio-Medicals Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Horiba Ltd.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Coagulation Market Segmentation
Table 2. North America Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzers
Table 3. North America Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 4. North America Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 5. Optical Technologies and Their Applications
Table 6. Mechanical Technologies and Their Applications
Table 7. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 8. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 9. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzers
Table 10. US Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 11. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 12. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 13. US Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 14. US Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 15. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 16. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 17. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzers
Table 18. Canada Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 19. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 20. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 21. Canada Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 22. Canada Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 23. Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million) – Disease Indication
Table 24. Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million) – Type
Table 25. Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million) – Clinical Laboratory Analyzers
Table 26. Mexico Coagulation Market Revenue and Forecast To 2030 (US$ million) – Offering
Table 27. Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million) – Diagnosis
Table 28. US Coagulation Market Revenue and Forecast to 2030 (US$ million) – Treatment
Table 29. Mexico Coagulation Market Revenue and Forecast To 2030 (US$ million) – Technology
Table 30. Mexico Coagulation Market Revenue and Forecast To 2030 (US$ million) – End User
Table 31. Recent Inorganic Growth Strategies in the Coagulation Market
Table 32. Recent Organic Growth Strategies in the Coagulation Market
Table 33. Glossary of Terms, Coagulation Market

LIST OF FIGURES

Figure 1. North America Coagulation Market Segmentation, By Country
Figure 2. North America Coagulation Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Coagulation Market Revenue (US$ million), 2020 – 2030
Figure 5. North America Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
Figure 6. Vitamin K Deficiency: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liver Disease: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Disseminated Intravascular Coagulation and Pulmonary Embolism: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Development of Circulating Anticoagulant: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Hemophilia: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Von Willebrand’s Disease: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. North America Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
Figure 14. Clinical Laboratory Analyzers: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Point-of-Care Testing Analyzers: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
Figure 17. Diagnosis: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Treatment: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 20. Optical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Mechanical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Electrochemical Technology: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
Figure 25. Clinical Laboratories: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Hospitals: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Others: North America Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. North America Coagulation Market, 2022 (US$)(million)
Figure 29. North America Coagulation Market, By Key Countries, 2022 and 2030 (%)
Figure 30. US Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 31. Canada Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 32. Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million)
Figure 33. Growth Strategies in the Coagulation Market

The List of Companies – North America Coagulation Market

1. Diagnostica Stago, Inc
2. F. Hoffmann-La Roche Ltd
3. Genrui Biotech Co., Ltd
4. Helena Laboratories Corporation
5. Horiba Ltd.
6. ImproGen Diagnostik Kimya San. & Tic. Ltd.Şti.
7. Siemens Healthineers AG
8. Sysmex Corp
9. Transasia Bio-Medicals Ltd

Reviews

There are no reviews yet.

Be the first to review “North America Coagulation Market Forecast to 2030”